What is the expected timeline for the company to file the overdue 10‑Q and regain compliance, and how might that timeline influence market perception?

Expected timeline: Nasdaq’s Listing Rule 5250(c)(1) gives a non‑compliant company typically 15 business days after a notice to cure the deficiency, after which the exchange may commence delisting procedures. The notice was issued on 26 August 2025, so the firm has until roughly mid‑September 2025 (around 13 September) to file the overdue Form 10‑Q and regain compliance. In practice, most companies accelerate the filing to avoid the delisting risk, so investors should expect the 10‑Q to appear within the next 2‑3 weeks, likely by early September at the latest.

Market perception impact: The mere fact of a late filing already injected negative sentiment (the news sentiment score is –40) and has pushed the stock lower on the “compliance‑risk” narrative. If Pathward posts the 10‑Q by the early‑September window, the market will likely view the cure as a relief catalyst, prompting a short‑term rebound and a tightening of the price range around recent support (≈ $X). Conversely, any further delay—especially past the 15‑day cure period—will amplify doubts about management’s control and raise the specter of a pending delisting, which could trigger sharper selling, widening volatility, and potentially open short‑selling or options‑selling opportunities. Traders should therefore monitor the SEC filing calendar closely: a prompt filing is a bullish signal to consider a buy‑on‑dip or a covered‑call strategy, while a prolonged gap justifies defensive positioning—tight stops, reduced exposure, or a tilt toward put spreads to profit from continued downside pressure.